FDA arah pengeluar ubat GLP-1 tambah amaran risiko gangguan penglihatan
Full story
The United States Food and Drug Administration has issued a directive to manufacturers of GLP-1 receptor agonist drugs. These companies must update their product safety labels. The updates are required to include warnings about the risk of vision impairment.
LOS ANGELES: Pentadbiran Makanan dan Ubat-ubatan Amerika Syarikat (FDA) pada Isnin mengarahkan pengeluar semua ubat agonis reseptor ‘glucagon-like peptide-1’ (GLP-1) mengemas kini label keselamatan produk masing-masing, lapor Xinhua.